Johnson & Johnson $JNJ Stake Trimmed by Miller Howard Investments Inc. NY

Key Points

• Miller Howard Investments cut its Johnson & Johnson stake by 21.4% in the third quarter, selling 86,267 shares and retaining 317,257 shares worth approximately $84.0 million. Institutional investors collectively own 69.55% of J&J.
• Analyst sentiment remains favorable, with a consensus “Moderate Buy” rating and an average price target of $275.92; HSBC raised its target to $320, while other firms maintained neutral or overweight ratings.
• J&J reported quarterly earnings and revenue slightly above expectations and reaffirmed its 2026 outlook, supported by newer medicines and medical devices. However, investors still face risks from Stelara’s declining sales, potential 2027 earnings pressure, legal issues and the stock’s premium valuation.

Miller Howard Investments Inc. NY cut its stake in Johnson & Johnson (NYSE:JNJ - Free Report) by 21.4% in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 317,257 shares of the company's stock after selling 86,267 shares during the quarter. Johnson & Johnson makes up approximately 2.3% of Miller Howard Investments Inc. NY's investment portfolio, making the stock its 5th largest position. Miller Howard Investments Inc. NY's holdings in Johnson & Johnson were worth $83,991,000 at the end of the most recent reporting period.

Several other hedge funds have also bought and sold shares of the stock. Westover Capital Advisors LLC raised its holdings in Johnson & Johnson by 3.8% in the 3rd quarter. Westover Capital Advisors LLC now owns 6,242 shares of the company's stock worth $1,653,000 after purchasing an additional 226 shares during the period. Peterson Wealth Services boosted its position in Johnson & Johnson by 1.9% during the third quarter. Peterson Wealth Services now owns 14,662 shares of the company's stock worth $3,882,000 after purchasing an additional 279 shares in the last quarter. Motive Wealth Advisors grew its holdings in Johnson & Johnson by 2.8% in the third quarter. Motive Wealth Advisors now owns 2,137 shares of the company's stock valued at $566,000 after purchasing an additional 59 shares during the period. Leo Wealth LLC acquired a new stake in Johnson & Johnson in the third quarter valued at approximately $27,789,000. Finally, Apollon Wealth Management LLC increased its position in shares of Johnson & Johnson by 6.3% in the third quarter. Apollon Wealth Management LLC now owns 171,511 shares of the company's stock valued at $45,406,000 after buying an additional 10,233 shares in the last quarter. Hedge funds and other institutional investors own 69.55% of the company's stock.

Analyst Upgrades and Downgrades

Several research analysts have recently weighed in on JNJ shares. HSBC upped their target price on Johnson & Johnson from $290.00 to $320.00 and gave the stock a "buy" rating in a research note on Thursday, September 10th. Wall Street Zen cut shares of Johnson & Johnson from a "buy" rating to a "hold" rating in a research note on Saturday, August 1st. Bank of America reissued a "neutral" rating and issued a $278.00 price target on shares of Johnson & Johnson in a report on Tuesday, September 29th. Morgan Stanley reduced their price objective on shares of Johnson & Johnson from $294.00 to $292.00 and set an "overweight" rating for the company in a research report on Thursday, October 15th. Finally, UBS Group set a $270.00 price objective on shares of Johnson & Johnson in a report on Wednesday, October 14th. One equities research analyst has rated the stock with a Strong Buy rating, seventeen have issued a Buy rating and eight have issued a Hold rating to the stock. According to MarketBeat, the company presently has an average rating of "Moderate Buy" and a consensus target price of $275.92.

Key Headlines Impacting Johnson & Johnson

Here are the key news stories impacting Johnson & Johnson this week:

• Positive Sentiment: Icotyde gains traction in plaque psoriasis. Independent physician research indicates that Johnson & Johnson’s oral therapy is being adopted quickly in U.S. dermatology practices and gaining share among oral advanced treatments. Earlier use could expand Icotyde’s revenue opportunity and delay treatment with more expensive biologics. Does Johnson & Johnson Have a New Edge in Plaque Psoriasis?
• Positive Sentiment: Newer products are helping offset Stelara’s decline. J&J’s stock has gained substantially over the past year as newer medicines compensate for pressure on Stelara, while the company works toward resolving ovarian talc claims. Johnson & Johnson Is Up 42% in a Year: Take Profits, or Buy More?
• Positive Sentiment: Medical-device evidence supports Impella. J&J presented a record 26 abstracts at TCT 2026, adding to more than two decades of data on the safety, efficacy and cost-effectiveness of its Impella heart pumps. The data may reinforce adoption of the cardiovascular device franchise. Johnson & Johnson Record 26 Abstracts at TCT 2026
• Positive Sentiment: Recent operating results remain supportive. J&J exceeded quarterly earnings expectations, with revenue rising year over year, and reaffirmed fiscal 2026 earnings guidance. Its diversified drug and device portfolio has also benefited from continued progress in arthritis treatments and regulatory expansion. Johnson & Johnson Strong Q3 Growth, But 2027 Could Test Its Earnings
• Neutral Sentiment: Analyst sentiment is generally favorable, but broker ratings are already reflected in the stock’s strong run and do not by themselves provide a new earnings catalyst. Johnson & Johnson Is Considered a Good Investment by Brokers
• Negative Sentiment: Investors face longer-term earnings and legal risks. Stelara’s erosion, potential 2027 earnings pressure and J&J’s premium valuation could limit further upside. Separately, Pomerantz announced an investigation into potential investor claims related to the company; the announcement is not a finding of wrongdoing but could add headline and litigation risk. Pomerantz Investor Alert Regarding Johnson & Johnson

Insiders Place Their Bets

In other news, EVP Jennifer L. Taubert sold 15,000 shares of the firm's stock in a transaction dated Monday, August 17th. The shares were sold at an average price of $263.36, for a total value of $3,950,400.00. Following the transaction, the executive vice president directly owned 194,451 shares of the company's stock, valued at approximately $51,210,615.36. This trade represents a 7.16% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this link. Also, EVP Timothy Schmid sold 33,597 shares of the business's stock in a transaction dated Wednesday, September 2nd. The stock was sold at an average price of $274.74, for a total transaction of $9,230,439.78. Following the transaction, the executive vice president owned 25,447 shares in the company, valued at $6,991,308.78. The trade was a 56.90% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 64,515 shares of company stock valued at $17,271,766 in the last 90 days. 0.16% of the stock is owned by insiders.

Johnson & Johnson Price Performance

NYSE:JNJ opened at $275.17 on Friday. The stock has a 50 day moving average of $265.64 and a two-hundred day moving average of $246.62. Johnson & Johnson has a 12 month low of $185.12 and a 12 month high of $281.07. The firm has a market cap of $662.42 billion, a P/E ratio of 25.45, a price-to-earnings-growth ratio of 2.68 and a beta of 0.21. The company has a current ratio of 1.02, a quick ratio of 0.74 and a debt-to-equity ratio of 0.44.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last issued its quarterly earnings results on Tuesday, October 13th. The company reported $2.59 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $2.53 by $0.06. Johnson & Johnson had a return on equity of 31.64% and a net margin of 16.20%. The firm had revenue of $25.40 billion for the quarter, compared to analyst estimates of $25.38 billion. During the same period in the previous year, the company posted $2.80 earnings per share. The business's revenue was up 5.9% on a year-over-year basis. Johnson & Johnson has set its FY 2026 guidance at 11.050-11.150 EPS. On average, analysts expect that Johnson & Johnson will post 11.12 earnings per share for the current fiscal year.

Johnson & Johnson Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, December 8th. Shareholders of record on Tuesday, November 24th will be paid a dividend of $1.34 per share. This represents a $5.36 annualized dividend and a yield of 1.9%. The ex-dividend date of this dividend is Tuesday, November 24th. Johnson & Johnson's payout ratio is 81.21%.

Johnson & Johnson Company Profile

Johnson & Johnson NYSE: JNJ is a global healthcare company headquartered in New Brunswick, New Jersey. Founded in 1886, the company develops and markets products and services for patients, healthcare professionals and institutions worldwide.

Johnson & Johnson operates through two principal segments: Innovative Medicine and MedTech. Innovative Medicine focuses on pharmaceuticals for areas such as immunology, oncology, neuroscience, infectious diseases and cardiovascular conditions.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.